A Salmonella mutant strain and the outer membrane vesicles produced by the mutant strain to resist Helicobacter pylori infection
By constructing Salmonella mutant strains, knocking out specific genes and expressing UreB and CagA antigens, effective outer membrane vesicles are formed, which solves the problem of insufficient prevention and treatment of Helicobacter pylori infection and achieves a significant anti-Herreb pylori infection effect.
Patent Information
- Application Number
- CN202310386503.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-12
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-04-12
AI Technical Summary
The prior art has limited means of preventing and treating Helicobacter pylori infection, especially in the early stage of using outer membrane vesicles, and lacks effective methods for constructing mutant strains to achieve prevention and treatment of Helicobacter pylori infection.
A Salmonella mutant strain was constructed, and the ΔrfbP, ΔfliC, ΔfljB and ΔOmpA genes were knocked out through homologous recombination, and the UreB and CagA antigens were expressed using the Hbp protein autotransport system to form outer membrane vesicles with anti-Herreb pylori infection effect.
The produced outer membrane vesicles significantly and effectively prevent and treat Helicobacter pylori infection, providing new prevention and treatment ideas and application prospects, and are superior to other antigen combinations and mutation strategies.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure HDA0004174208790000011
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of genetic engineering and the field of anti-Helicobacter pylori infection, and specifically relates to a Salmonella mutant and an anti-Helicobacter pylori infection outer membrane vesicle produced by the mutant. Background Art
[0002] Helicobacter pylori was discovered by Barry J. Marshall and J. Robin Warren. The main symptoms of infection with Helicobacter pylori are acid reflux, heartburn, stomach pain and bad breath. Infection with Helicobacter pylori can also cause chronic gastritis. Although the course of the disease is slow, it is prone to recurrence.
[0003] At present, for the treatment of Helicobacter pylori infection, in addition to the use of triple therapy (proton pump inhibitors or bismuth combined with two antibiotics) and quadruple therapy (bismuth, proton pump inhibitors and two antibiotics), common therapeutic drugs also have certain natural medicines, such as the pharmaceutical composition disclosed in CN101209271B. In recent years, some bacterial agents have occasionally been used to achieve the preventive and therapeutic effects on Helicobacter pylori infection, such as CN102174450B, which discloses a plant lactobacillus that resists Helicobacter pylori infection. It can be seen from this that the means for resisting Helicobacter pylori infection are relatively limited at present, and more alternative treatment options are urgently needed.
[0004] Outer membrane vesicles have more superior immune stimulation ability than live bacteria, and as vaccines and delivery carriers, they are attracting more and more attention from researchers. On the one hand, they can avoid the safety risks of live bacterial carriers, and on the other hand, due to the characteristics of their lipid bilayers, they can encapsulate the delivered small molecule drugs and prevent them from being cleared too quickly by the body. Research on the use of outer membrane vesicles to achieve related pathogenic bacteria infection is still in its infancy, with only sporadic reports, such as CN111793591B using mutant outer membrane vesicles to achieve prevention and treatment of Helicobacter pylori infection.
[0005] In summary, how to construct relevant mutant strains and use their outer membrane vesicles to prevent and treat Helicobacter pylori infection is a technical problem that urgently needs to be solved in this field. Summary of the invention
[0006] In view of the shortcomings and needs of the prior art, the object of the present invention is to provide a Salmonella mutant strain, the outer membrane vesicles produced by the mutant strain have good anti-Helicobacter pylori infection effect.
[0007] In order to achieve the above technical objectives, the present invention adopts the following technical solutions:
[0008] A mutant strain of Salmonella has deletion mutations in ΔrfbP, ΔfliC, ΔfljB and ΔOmpA genes, and presents and simultaneously expresses UreB and CagA antigens.
[0009] As an embodiment of the present invention, the mutant strain is classified and named Salmonella tpyhimurium QS0074, with a preservation number of CCTCC M 2023192, and is preserved in the China Center for Type Culture Collection on February 24, 2023.
[0010] As one embodiment of the present invention, the UreB and CagA antigens are expressed by the Hbp protein autotransport system; the nucleotide sequence of the gene rfbP is shown in SEQ ID No.1, the nucleotide sequence of the gene fliC is shown in SEQ ID No.2, the nucleotide sequence of the gene fljB is shown in SEQ ID No.3, the nucleotide sequence of the gene OmpA is shown in SEQ ID No.4, the nucleotide sequence of the gene UreB is shown in SEQ ID No.5, the nucleotide sequence of the gene CagA is shown in SEQ ID No.6, and the gene nucleotide sequence of the Hbp autotransport system expression box is shown in SEQ ID No.7.
[0011] The present invention also provides a method for constructing the above mutant strain, the construction method comprising the following steps:
[0012] (1) knocking out the genes rfbP, fliC, fljB, and OmpA by homologous recombination;
[0013] (2) by transferring into an expression plasmid, the gene expression fragments of UreB and CagA antigens are constructed into a plasmid using the Hbp protein autotransport system, and the plasmid is transferred into Salmonella by electroporation, thereby finally constructing the Salmonella mutant strain;
[0014] Preferably, the expression plasmid is a pYA3332 template plasmid;
[0015] More preferably, the method for constructing the plasmid in step (2) comprises the following steps:
[0016] <1> The Hbp autotransporter expression cassette from Salmonella typhimurium was cloned into the vector pYA3332 using the Gibson assembly kit in one step.
[0017] <2> The coding gene sequences of tumor antigen UreB and CagA antigen were cloned into the Hbp autotransporter expression cassette respectively using the Gibson assembly kit to express the two antigens on the outer membrane surface of the mutant strain.
[0018] As an embodiment of the present invention, the step (1) specifically comprises the following steps:
[0019] <1> Construction of homologous recombination plasmids PI11570-rfbP, PI11570-fliC, PI11570-fljB, and PI11570-OmpA;
[0020] <2> Preparation of competent Salmonella Typhimurium S100;
[0021] <3> Step <1> The homologous recombinant plasmid obtained was transformed into the competent Salmonella Typhimurium S100 strain by electroporation. The electroporation cup was moved into the electroporator and electroporated at 2500 volts for 4 milliseconds.
[0022] <4> The liquid in the electroporation cup was transferred to a solid culture medium for Salmonella without antibiotics, cultured in a microaerobic environment for 48 hours, subcultured to a culture medium containing the corresponding antibiotics for 48 hours, and then cultured in a resistance culture medium for 48 hours. The resulting single clone was the successfully electroporated bacterium.
[0023] <5> The mutant strain without rfbP, fliC, fljB and OmpA was obtained by PCR screening;
[0024] Preferably, the step <2> The preparation method of Salmonella Typhimurium S100 comprises the following steps:
[0025] 1> Cultivate Salmonella Typhimurium S100 for 36-48 hours until the logarithmic phase, take 3 ml of the electroporation solution that has been pre-cooled on ice into a culture dish, collect 1 ml of the bacteria into a clean 1.5 ml centrifuge tube, and adjust the bacterial concentration to 5×10 9 CFU / ml;
[0026] 2> Centrifuge at 4°C for 5 min at 6000 rpm and repeat washing three times;
[0027] 3> After discarding the supernatant, resuspend the cells in 1 ml of pre-cooled electroporation solution and adjust the bacterial concentration to 5×10 8 CFU / ml, that is, the competent medium is ready for use.
[0028] As an embodiment of the present invention, the construction steps of the homologous recombination plasmids PI11570-rfbP, PI11570-fliC, PI11570-fljB, and PI11570-OmpA are as follows:
[0029] 1) Primer design:
[0030] rfbP-1F: 5’CAACTGATAAAAGTCAATCC3’
[0031] rfbP-1R: 5’GTAAGCTTACCTGCAGGTTAATCCTCACCCTCTGA3’
[0032] rfbP-2F: 5’GATTAACCTGCAGGTAAGCTTACCGAGAAGTACTGA3’
[0033] rfbP-2R: 5’ATACGACGAGGCGTTTCGAG3’
[0034] fliC-1F: 5’CGTTCTTTGTCAGGTCTGTC3’
[0035] fliC-2R: 5’GATTAGCGGCCGCGATCTTTTCCTTATCAATTA3’
[0036] fliC-2F: 5’AAGATCGCGGCCGCTAATCCGGCGATTGATTCAC3’
[0037] fliC-2R: 5’TGTACCCGGCACAGACGGTC3’
[0038] fljB-1F: 5’AGTGAGCTCCACGTTCATGT3’
[0039] fljB-1R: 5’AATTAGCGGCCGCAAAATTTTCCTTTTGGAAGG3’
[0040] fljB-2F: 5’ATTTTGCGGCCGCTAATTTATTTCGTTTTATTC3’
[0041] fljB-2R: 5’GTCATTACCTGATAATTCTTC3’
[0042] ompA-1F: 5’CATCCTCTCACACAACGAGAC3’
[0043] ompA-1R: 5’CTGCAGGAATGCGGCCGCCGGGGGATCTGCTCAATATT3’
[0044] ompA-2F: 5'CGGCCGCATTCCTGCAGGTAAGTTATCGTCTGGTAGAAAAAC3'
[0045] ompA-2R:5'CATATGAATCCGGAACTGGTC3'
[0046] 2) extracting Salmonella Typhimurium S100 genomic DNA in the logarithmic growth phase as a template, amplifying with left and right homologous arm primers respectively, obtaining amplified products of the left and right homologous arms, and digesting the recovered products with restriction sites on the primers respectively, i.e., digesting the left homologous arm with EcoR I and Pst I, and digesting the right homologous arm with Cla I and BamH I, to obtain digested products of the left and right homologous arms;
[0047] 3) The vector plasmids were then digested with enzymes, and the resulting vector digestion products were ligated to the left and right homologous arms respectively under the action of T4 ligase and transformed into the Escherichia coli strain TOP10 to obtain recombinant plasmids PI11570-rfbP, PI11570-fliC, PI11570-fljB, and PI11570-OmpA.
[0048] As an embodiment of the present invention, the method for constructing the Hbp self-transport system expression plasmid vector comprises the following steps:
[0049] <1> Primer design:
[0050] Hbp-F:5'ACGCGTATATGCAAGTCCACCGGTTTAAG3'
[0051] Hbp-R:5'TTCGAGCTGACTGACTGTAAGCGTACAGCCTG 3'
[0052] <2> The genomic DNA of Salmonella Typhimurium S100 in the logarithmic growth phase was extracted as a template, and the pYA3332 linearized plasmid was used as a template for amplification with corresponding primers, and the amplified products of the corresponding fragments were obtained respectively. The products were cloned in one step using the Gibson assembly kit, and the products were transformed into the Escherichia coli strain TOP10 to obtain the recombinant plasmid pYA3332-Hbp;
[0053] And / or, the method for constructing the expression plasmid of UreB and CagA antigens comprises the following steps:
[0054] <1> Primer design:
[0055] UreB-F:5'TGCTGACAAAGAACTGGGTTCTACCGCAATTTTTG3'
[0056] UreB-R:5'GAAACAGTTCCTGAGTCGGCGTTCGATCACCCT3'
[0057] CagA-F:5'TGCCACCCTGAGTCTGAACAGCCTACTGATTACTTTGGTAAC3'
[0058] CagA-R:5'CGCTGTTACGACGCATTGAGACTTAAGATTTCTGGAAACCAC3'
[0059] pYA3332-Hbp-UreB-F:5'AGGGGTGATCGAACGCCATGACGTAACTGACGATTGC3'
[0060] pYA3332-Hbp-UreB-R:5'CAAAAATTGCGGTAGAACCAGTAAACCTTGGCGACGTG3'
[0061] pYA3332-Hbp-CagA-F:
[0062] 5'GTGGTTTCCAGAAATCTTAAAGCGCCGGCCTGAAGGTAATC3'
[0063] pYA3332-Hbp-CagA-R:5'GTTACCAAAGTAATCAGTGCGCCGAGAGCGATTGA3'
[0064] <2> Primers UreB-F and UreB-R were used to amplify the sequence corresponding to UreB using Salmonella Typhimurium S100 as a template, and primers pYA3332-Hbp-UreB-F and pYA3332-Hbp-UreB-R were used to amplify the vector fragment using pYA3332-Hbp as a template, and the amplified products of the corresponding fragments were obtained respectively, and one-step cloning was performed using Gibson assembly kit, and the products were transformed into Escherichia coli strain TOP10 to obtain the recombinant plasmid pYA3332-Hbp-UreB;
[0065] <3> Primers CagA-F and CagA-R were used to amplify the sequence corresponding to CagA using Salmonella Typhimurium S100 as a template. Primers pYA3332-Hbp-CagA-F and pYA3332-Hbp-CagA-R were used to amplify the vector fragment using pYA3332-Hbp-UreB as a template. The amplification products of the corresponding fragments were obtained respectively, and the Gibsonassembly kit was used for one-step cloning. The products were transformed into Escherichia coli strain TOP10 to obtain the recombinant plasmid pYA3332-Hbp-UreB-CagA.
[0066] The present invention also provides outer membrane vesicles that resist Helicobacter pylori infection produced by the mutant strain or the mutant strain constructed by the above construction method.
[0067] The present invention also provides a preparation for resisting Helicobacter pylori infection, wherein the preparation comprises the outer membrane vesicles mentioned above.
[0068] The present invention also provides application of the outer membrane vesicles in preparing drugs for resisting Helicobacter pylori infection.
[0069] In the process of research, the present invention tried a variety of mutant construction strategies. As shown in the test examples of the present invention, the outer membrane vesicles obtained by other strategies generally have poor effects in resisting Helicobacter pylori infection. For example, knocking out different types of outer membrane proteins OmpA, OmpC and OmpD, or knocking out them in combination, the effect is not as strong as the ability of OmpA to induce immune response alone. At the same time, replacing the presented UreB with VacA, or replacing the presented CagA with VacA, or even presenting UreB, VacA and CagA antigens at the same time, the effect of the anti-Helicobacter pylori infection obtained is significantly lower than that of the present invention.
[0070] Beneficial effects of the present invention:
[0071] The outer membrane vesicles produced by the mutant strain obtained in the present invention have obvious effect of resisting Helicobacter pylori infection. The present invention provides a new idea for preventing and treating Helicobacter pylori infection and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] Figure 1 This is a schematic diagram of the construction and working of the Hbp self-transport system;
[0073] Figure 2 Immunization procedures for evaluating vector delivery efficiency for the present invention;
[0074] Figure 3 The levels of IgG antibodies against UreB produced by mice immunized in different test groups at week 8;
[0075] Figure 4 The levels of IgA antibodies against UreB produced by mice in different test groups at 8 weeks after immunization;
[0076] Figure 5 An immunization program for evaluating the immune protection efficiency of different antigen combinations for the present invention;
[0077] Figure 6 The protective effect of different antigen combinations encapsulated in outer membrane vesicles against Helicobacter pylori infection - urease content determination results;
[0078] Figure 7 The protective effect of different antigen combinations encapsulated in outer membrane vesicles against Helicobacter pylori infection - the results of gastric bacterial load measurement. DETAILED DESCRIPTION
[0079] The present invention is described in detail below through examples. It is necessary to point out that the following examples are only used to further illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. Some non-essential improvements and adjustments made by technical personnel in this field based on the above invention content still fall within the scope of protection of the present invention.
[0080] Example 1
[0081] 1. Construction and identification of homologous recombination plasmids used for the construction of Salmonella mutant strains
[0082] (1) Primer design and PCR amplification
[0083] According to the standard strain of Salmonella enterica serovar Typhimuriumstr.S100 (hereinafter referred to as Salmonella Typhimurium S100), fusion PCR primers were designed to amplify the upstream homology arms and downstream homology arms of the rfbP gene, fliC gene, fljB gene, and OmpA gene, respectively. The above primers were synthesized by GeneCare, and the primer sequences are as follows:
[0084] rfbP-1F:5'CAACTGATAAAAGTCAATCC3'
[0085] rfbP-1R: 5'GTAAGCTTACCTGCAGGTTAATCCTCACCCTCTGA3'
[0086] rfbP-2F: 5'GATTAACCTGCAGGTAAGCTTACCGAGAAGTACTGA3'
[0087] rfbP-2R: 5'ATACGACGAGGCGTTTCGAG3'
[0088] fliC-1F: 5'CGTTCTTTGTCAGGTCTGTC3'
[0089] fliC-2R: 5'GATTAGCGGCCGCGATCTTTTCCTTATCAATTA3'
[0090] fliC-2F: 5'AAGATCGCGGCCGCTAATCCGGCGATTGATTCAC3'
[0091] fliC-2R: 5'TGTACCCGGCACAGACGGTC3'
[0092] fljB-1F:5'AGTGAGCTCCACGTTCATGT3'
[0093] fljB-1R:5'AATTAGCGCCGCAAAATTTTCCTTTTGGAAGG3'
[0094] fljB-2F:5'ATTTTGCGGCCGCTAATTTATTTCGTTTTATTC3'
[0095] fljB-2R:5'GTCATTACCTGATAATTCTTC3'
[0096] ompA-1F:5'CATCCTCTCACACAACGAGAC3'
[0097] ompA-1R: 5'CTGCAGGAATGCGGCCGCCGGGGGATCTGCTCAATATT3'
[0098] ompA-2F: 5'CGGCCGCATTCCTGCAGGTAAGTTATCGTCTGGTAGAAAAAC3'
[0099] ompA-2R:5'CATATGAATCCGGAACTGGTC3'
[0100] The freeze-dried Salmonella Typhimurium S100 was inoculated into a Brucella broth plate for overnight culture. The next day, a single colony was picked and inoculated into a Brucella broth liquid culture medium, and cultured at 37°C and 180 r / min for 24-32 hours to extract the bacterial genome (the genome was extracted using the bacterial genome extraction kit of Tiangen Biochemical, and the genome was extracted according to the operating procedures in the instruction manual).
[0101] PCR amplification reaction:
[0102] 1) rfbP gene:
[0103] The reaction was carried out in a 50 μL system, and the reaction system was as follows: 1 μL template DNA, 25 μL 2× high-fidelity DNA enzyme premix purchased from Takara Biotech (Dalian) Co., Ltd., 1 μL upstream primer, 1 μL downstream primer, and 22 μL ddH2O.
[0104] The amplification conditions were: denaturation at 94°C for 5 min followed by cycling, with cycle parameters of 94°C for 10 sec, 55°C for 15 sec, and 72°C for 10 sec. After 35 cycles, extension was performed at 72°C for 10 min. The amplified PCR products were analyzed by 1% agarose gel electrophoresis, and the sizes of the two amplified fragments were 450 bp and 483 bp, respectively, which were comparable to the expected sizes.
[0105] 2) fliC gene:
[0106] The reaction was carried out in a 50 μL system, and the reaction system was as follows: 1 μL template DNA, 25 μL 2× high-fidelity DNA enzyme premix purchased from Takara Biotech (Dalian) Co., Ltd., 1 μL upstream primer, 1 μL downstream primer, and 22 μL ddH2O.
[0107] The amplification conditions were: denaturation at 94°C for 5 min followed by cycling, with cycle parameters of 94°C for 10 sec, 55°C for 15 sec, and 72°C for 10 sec. After 35 cycles, extension was performed at 72°C for 10 min. The amplified PCR products were analyzed by 1% agarose gel electrophoresis, and the sizes of the two amplified fragments were 352 bp and 463 bp, respectively, which were comparable to the expected sizes.
[0108] 3) fljB gene:
[0109] The reaction was carried out in a 50 μL system, and the reaction system was as follows: 1 μL template DNA, 25 μL 2× high-fidelity DNA enzyme premix purchased from Takara Biotech (Dalian) Co., Ltd., 1 μL upstream primer, 1 μL downstream primer, and 22 μL ddH2O.
[0110] The amplification conditions were: denaturation at 94°C for 5 min followed by cycling, with cycle parameters of 94°C for 10 sec, 55°C for 15 sec, and 72°C for 10 sec. After 35 cycles, extension was performed at 72°C for 10 min. The amplified PCR products were analyzed by 1% agarose gel electrophoresis, and the sizes of the two amplified fragments were 563 bp and 623 bp, respectively, which were comparable to the expected sizes.
[0111] 4) OmpA gene
[0112] The reaction was carried out in a 50 μL system, and the reaction system was as follows: 1 μL template DNA, 25 μL 2× high-fidelity DNA enzyme premix purchased from Takara Biotech (Dalian) Co., Ltd., 1 μL upstream primer, 1 μL downstream primer, and 22 μL ddH2O.
[0113] The amplification conditions were: denaturation at 94°C for 5 min followed by cycling, with cycle parameters of 94°C for 10 sec, 56°C for 5 sec, and 72°C for 10 sec. After 35 cycles, extension was performed at 72°C for 10 min. The amplified PCR products were analyzed by 1% agarose gel electrophoresis, and the sizes of the two amplified fragments were 342 bp and 367 bp, respectively, which were comparable to the expected sizes.
[0114] (2) Construction of homologous recombination plasmid
[0115] 1) PI11570-rfbP homologous recombination plasmid
[0116] The homology arm fragments obtained previously were digested with the restriction sites on the primers, that is, the left homology arm was digested with EcoR I and Pst I, and the right homology arm was digested with Cla I and BamH I, to obtain the products after the digestion of the left and right homology arms. The reaction system was: 20 μL template, 4 μL buffer, 1 μL restriction endonuclease; the reaction conditions were: 37°C for 2 hours. After the reaction was completed, the fragments were recovered by agarose gel electrophoresis and set aside; the vector plasmid was digested separately, and the reaction system was the same as above. The obtained vector digestion products were connected to the left and right homology arms respectively under the action of T4 ligase, and incubated in a water bath at 16°C overnight, and transformed into the Escherichia coli strain TOP10 to obtain the recombinant plasmid PI11570-rfbP. The identification results confirmed that the constructed suicide plasmid was correct.
[0117] 2) PI11570-fliC homologous recombination plasmid
[0118] The homology arm fragments obtained previously were digested with the restriction sites on the primers, that is, the left homology arm was digested with EcoR I and Pst I, and the right homology arm was digested with Cla I and BamH I, to obtain the products after the digestion of the left and right homology arms. The reaction system was: 20 μL template, 4 μL buffer, 1 μL restriction endonuclease; the reaction conditions were: 37°C for 2 hours. After the reaction was completed, the fragments were recovered by agarose gel electrophoresis and set aside; the vector plasmid was digested separately, and the reaction system was the same as above. The obtained vector digestion products were connected to the left and right homology arms respectively under the action of T4 ligase, incubated in a water bath at 16°C overnight, and transformed into the Escherichia coli strain TOP10 to obtain the recombinant plasmid PI11570-fliC. The identification results confirmed that the constructed suicide plasmid was correct.
[0119] 3) PI11570-fljB homologous recombination plasmid
[0120] The homology arm fragments obtained previously were digested with the restriction sites on the primers, that is, the left homology arm was digested with EcoR I and Pst I, and the right homology arm was digested with Cla I and BamH I, to obtain the products after the digestion of the left and right homology arms. The reaction system was: 20 μL template, 4 μL buffer, 1 μL restriction endonuclease; the reaction conditions were: 37°C for 2 hours. After the reaction was completed, the fragments were recovered by agarose gel electrophoresis and set aside; the vector plasmid was digested separately, and the reaction system was the same as above. The obtained vector digestion products were connected to the left and right homology arms respectively under the action of T4 ligase, and incubated in a water bath at 16°C overnight, and transformed into the Escherichia coli strain TOP10 to obtain the recombinant plasmid PI11570-fljB. The identification results confirmed that the constructed suicide plasmid was correct.
[0121] 4) PI11570-OmpA homologous recombination plasmid
[0122] The homology arm fragments obtained previously were digested with the restriction sites on the primers, that is, the left homology arm was digested with EcoR I and Pst I, and the right homology arm was digested with Cla I and BamH I, to obtain the products after the digestion of the left and right homology arms. The reaction system was: 20 μL template, 4 μL buffer, 1 μL restriction endonuclease; the reaction conditions were: 37°C for 2 hours. After the reaction was completed, the fragments were recovered by agarose gel electrophoresis and set aside; the vector plasmid was digested separately, and the reaction system was the same as above. The obtained vector digestion products were connected to the left and right homology arms respectively under the action of T4 ligase, incubated in a water bath at 16°C overnight, and transformed into the Escherichia coli strain TOP10 to obtain the recombinant plasmid PI11570-OmpA. The identification results confirmed that the constructed suicide plasmid was correct.
[0123] 2. Construction and identification of a Salmonella enterica serovar Typhimurium str.S100ΔrfbPΔfliCΔfljBΔOmpA gene deletion mutant (QS0071)
[0124] (1) Construction and identification of single gene deletion mutants
[0125] First, prepare the electroporation competent state of Salmonella Typhimurium. Cultivate Salmonella Typhimurium S100 for 36-48 hours until the logarithmic phase. Take 3 ml of the electroporation solution that has been pre-cooled on ice and put it in a culture dish. Collect 1 ml of the bacteria in a clean 1.5 ml centrifuge tube and adjust the bacterial concentration to 5*10 9CFU / ml. Centrifuge at 6000rpm for 5min at 4°C and repeat washing three times. Discard the supernatant and resuspend the cells in 1ml pre-cooled electroporation solution. Adjust the cell concentration to 5*10 8 CFU / ml, that is, the competent state is prepared for use. The constructed homologous recombination plasmid PI11570-futB is transformed into the competent state of Salmonella Typhimurium S100 by electrotransformation, and the electrotransformation cup is moved into the electrotransformer, and an electric shock is performed at 2500 volts for 4 milliseconds. The liquid in the electrotransformation cup is transferred to a solid medium for Salmonella without antibiotics, cultured for 48 hours, and then subcultured to a medium containing corresponding antibiotics and cultured for 48 hours. The resulting monoclonal is the successfully electrotransformed bacterium, and a single colony is picked for PCR identification.
[0126] PCR identification: Extract the genomic DNA of the rfbP mutant strain Salmonella enterica serovar Typhimuriumstr.S100-ΔfutB, and use primers rfbP-left up and rfbP-right down to amplify the upstream and downstream homology arm fragments to see if the upstream and downstream homology arm fragments of about 920bp lacking the rfbP gene can be amplified. If the corresponding fragment can be amplified, it means that the result is consistent with the expectation, and it can be preliminarily identified that the mutant strain is successfully constructed.
[0127] (2) Construction and identification of multiple gene deletion mutants
[0128] On the basis of single gene knockout, a single knockout gene deletion mutant was prepared, and the remaining homologous recombination plasmids were transferred into the single knockout gene deletion mutant by electroporation. The electroporation cup was moved into the electroporator and electroporated at 2500 volts for 4 milliseconds. The liquid in the electroporation cup was transferred to a solid culture medium of Salmonella without antibiotics, cultured for 48 hours, and then subcultured to a culture medium containing corresponding antibiotics for 48 hours. The resulting monoclonal clone was the successfully electroporated bacteria, and a single colony was picked for PCR identification.
[0129] PCR identification: Extract the genomic DNA of the mutant strain, and use the corresponding gene knockout primers to amplify the upstream and downstream homology arm fragments to see if the upstream and downstream homology arm fragments of the corresponding size that lack the corresponding gene can be amplified. If the corresponding fragment can be amplified, it means that the result is consistent with the expectation, and the mutant strain can be preliminarily identified to be successfully constructed. The above-described method was finally used to construct the Salmonella enterica serovar Typhimurium str.S100ΔrfbPΔfliCΔfljBΔOmpA gene deletion mutant (abbreviated as QS0071).
[0130] 3. Construction and identification of a gene deletion mutant of Salmonella enterica serovar Typhimurium str.S100ΔrfbPΔfliCΔfljBΔOmpA-plasmid Hbp+UreB-CagA (QS0074)
[0131] (1) Construction and identification of expression plasmids for UreB and CagA antigens
[0132] Primers UreB-F and UreB-R were used to amplify the sequence corresponding to UreB with Salmonella Typhimurium S100 as a template, and primers pYA3332-Hbp-UreB-F and pYA3332-Hbp-UreB-R were used to amplify the vector fragment with pYA3332-Hbp as a template to obtain the amplified products of the corresponding fragments, which were cloned in one step using the Gibson assembly kit and transformed into the Escherichia coli strain TOP10 to obtain the recombinant plasmid pYA3332-Hbp-UreB. Based on the plasmid, primers CagA-F and CagA-R were used to amplify the vector fragment with Salmonella Typhimurium S100 was used as a template to amplify the sequence corresponding to CagA, and the primers pYA3332-Hbp-CagA-F and pYA3332-Hbp-CagA-R were used to amplify the vector fragment with pYA3332-Hbp-UreB as a template, and the amplified products of the corresponding fragments were obtained respectively. The Gibsonassembly kit was used for one-step cloning, and the products were transformed into the Escherichia coli strain TOP10 to obtain the recombinant plasmid pYA3332-Hbp-UreB-CagA. Finally, the plasmids expressing UreB and CagA antigens were successfully constructed using the amplification primers of UreB and CagA, respectively.
[0133] (2) Construction of the final antigen expression strain QS0074
[0134] The obtained pYA3332-Hbp-UreB-CagA plasmid was transferred into the prepared QS0071 strain electroporation competent medium by electroporation, and the electroporation cup was moved into the electroporation instrument, and the electroporation was performed at 2500 volts for 4 milliseconds. The liquid in the electroporation cup was transferred to a common agar plate containing ampicillin resistance and cultured for 48 hours. The resulting single clone was the successfully electroporated bacteria, and a single colony was picked for PCR identification, and finally the QS0074 strain was obtained.
[0135] Test example
[0136] Referring to the strategy of constructing QS0074 in Example 1, the present invention attempted to construct a variety of mutant strains, as shown in Table 1. In addition to using QS0071 in Example 1 as a vector strain, QS0091, QS00101, and QS00111 were also attempted as vector strains; in addition to using QS0074 in Example 1 as a test strain, a variety of other test strains were also used for testing.
[0137] Table 1
[0138]
[0139]
[0140] The nucleotide sequence of the gene OmpC is shown in SEQ ID No. 8. When constructing the homologous recombination plasmid PI11570-OmpC, the primers designed are:
[0141] ompC-1F: 5'GCCAATACGCAGCGCCGAGGTCACG3'
[0142] ompC-1R: 5'ACCTGCAGGATGCGGCCGCGGTCAGCAAAAGATG3'
[0143] ompC-2F: 5'CCGCGGCCGCATCCTGCAGGTGTTATTAACCCTCTG3'
[0144] ompC-2R: 5'ATAGGGGTAAACAGACATTCAGAAG3'
[0145] The nucleotide sequence of the gene OmpD is shown in SEQ ID No. 9. When constructing the homologous recombination plasmid PI11570-OmpD, the primers designed are:
[0146] ompD-1F:5'AAAGTTAATGATGATAGCGG3'
[0147] ompD-1R:5'CTGCAGGAATGCGGCCGCGTTATTAACCCTCTGTTATA3'
[0148] ompD-2F:5'CGGCCGCATTCCTGCAGGTAATCTCGATGGATATCGAAC3'
[0149] ompD-2R:5'CGTTAAAGCGCATCAGCGCG3'
[0150] The nucleotide sequence of the gene VacA is shown in SEQ ID No. 10. When constructing the homologous recombination plasmid PI11570-VacA, the primers designed are:
[0151] VacA-F:5'GCGTGAAACATAACGGTACCTTTATGTTGTTTGTG3'
[0152] VacA-R:5'CATATGTGGTGGGTTCCCTGTGTTAATTGGTACCTGTAGAAAC3'
[0153] During the construction process, when presenting different antigens, pYA3332 was used as a template, and the Hbp autotransport system with a total length of 7791 bp was first constructed into pYA3332, and then Figure 1 The three main antigen proteins UreB, VacA and CagA were constructed in the corresponding positions in the order of plasmids (plasmid Hbp+UreB-VacA-CagA, plasmidHbp+UreB-VacA, plasmid Hbp+UreB-CagA, plasmidHbp+VacA-CagA).
[0154] The outer membrane vesicles purified from the test strains (QS0072, QS0082, QS0092, QS00102, QS00112, QS00122, QS00132) were used to immunize mice. The immunization procedure was as follows: Figure 2 At the eighth week, the antibody levels (IgG and IgA) against UreB in mouse serum were measured to evaluate the presentation efficiency of outer membrane vesicles for antigen presentation and to identify the optimal carrier. Figure 3 and Figure 4 The results show that the ompA mutation has the best antigen presentation effect and can produce an immunostimulatory effect superior to that produced by other single mutations and mutation combinations. Therefore, the ompA mutation was selected for subsequent screening and identification of Helicobacter pylori antigen combinations.
[0155] The outer membrane vesicles produced by the test strains QS0071, QS0072, QS0073, QS0074, and QS0075 were used to immunize mice. The immunization procedure was as follows: Figure 5 As shown. After being infected with Helicobacter pylori in advance, mice were immunized with outer membrane vesicles, and the protective effects of different antigen combinations against Helicobacter pylori were evaluated using urease assay and bacterial load determination at week 9. Figure 6 and Figure 7 The results show that the protection effect produced by the simultaneous presentation of UreB and CagA by outer membrane vesicles is the best, better than other combinations of two or even better than the combination of three antigens together.
Claims
1. A mutant strain of Salmonella, characterized in that: The mutant strain has gene deletion mutations of ΔrfbP, ΔfliC, ΔfljB and ΔOmpA, and presents and simultaneously expresses UreB and CagA antigens; the UreB and CagA antigens are expressed by the Hbp protein self-transport system; the nucleotide sequence of the gene rfbP is shown in SEQ ID No.1, the nucleotide sequence of the gene fliC is shown in SEQ ID No.2, the nucleotide sequence of the gene fljB is shown in SEQ ID No.3, the nucleotide sequence of the gene OmpA is shown in SEQ ID No.4, the nucleotide sequence of the gene UreB is shown in SEQ ID No.5, the nucleotide sequence of the gene CagA is shown in SEQ ID No.6, and the gene nucleotide sequence of the Hbp self-transport system expression box is shown in SEQ ID No.
7.
2. A Salmonella mutant according to claim 1, characterized in that: The mutant strain is classified and named Salmonella tpyhimurium QS0074, with a preservation number of CCTCC M2023192. It is preserved in the China Center for Type Culture Collection on February 24, 2023.
3. An outer membrane vesicle for resisting Helicobacter pylori infection, characterized in that: The outer membrane vesicles are produced by the Salmonella mutant strain according to claim 1 or 2.
4. A preparation for resisting Helicobacter pylori infection, characterized in that: The preparation comprises the outer membrane vesicles according to claim 3.
5. Use of the outer membrane vesicles as claimed in claim 3 in the preparation of drugs for resisting Helicobacter pylori infection.
